Both of the organisms in NARAMUNE-2 are avirulent so that they can be safely administered intranasally with little or no symptoms of disease. By instilling these organisms into the nasal passages, it becomes possible for these agents to infect target cells of the nasal-pharyngeal region, mimicking the pathogenesis of natural field infection. A very small percentage of dogs may show sneezing, coughing or nasal discharge for 3-10 days following vaccination. While these are usually temporary symptoms, antibacterial therapy may be indicated.
Dosage and Administration: Rehydration: Rehydrate to desired dose volume with accompanying sterile diluent. For five 0.5 mL doses, reconstitute with 2.5 mL of diluent. For five 1 mL doses, reconstitute with 5 mL of diluent. Shake well and use immediately.
Using aseptic technique, administer entire dose intranasally. Use enclosed applicator tip on hub of syringe in place of syringe needle. Apply new nasal applicator tip for each dog vaccinated. Do not vaccinate puppies under 3 weeks of age. Puppies vaccinated between 3 and 6 weeks of age should be revaccinated at 6 weeks of age. Annual revaccination is recommended.
Precaution(s): Store out of direct sunlight at a temperature between 35-45°F (2-7°C). Use entire contents when first opened. Burn containers and all unused contents.
Caution(s): For intranasal use in dogs only; do not vaccinate dogs parenterally. Anaphylactoid reactions may occur.
Antidote(s): Epinephrine
